5-Fluorouracil (5-FU) is a commonly used chemotherapy agent in clinical oncology practice. Two of its major side effects are mucositis and diarrhoea. The structure of mucins offers mucosal protection, and allows maintenance of intestinal flora by providing attachment sites and preventing bacterial overgrowth and/or penetration. The aim of this study was to investigate changes in mucin secretion and microflora following treatment with 5-FU. Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. Rats were killed at various time points after treatment. Control rats received no treatment. Jejunum, colon and faecal samples were collected. Standard microbiological culture techniques were used to identify bacteria, and real-time PCR was used to quantify bacteria in faecal samples. Goblet cells and cavitated goblet cells (having undergone mucus exocytosis) were also counted. Statistical analysis was carried out using Kruskal-Wallis test, a non-parametric method of testing equality of group medians. Following treatment with 5-FU, we showed decreases in Clostridium spp., Lactobacillus spp. and Streptococcus spp., and an increase in Escherichia spp. in the jejunum. In the colon, 5-FU caused decreases in Enterococcus spp., Lactobacillus spp. and Streptococcus spp. Real-time PCR of faecal samples showed decreasing trends in Lactobacillus spp. and Bacteroides spp., and an increasing trend in E. coli. Significant increases (P < 0.05) were seen in Clostridium spp. and Staphylococcus spp. at 24 h. Goblet cell numbers decreased significantly in the jejunum from 24–72 h, with a significant increase in the percentage of cavitated goblet cells. In conclusion, 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes could result in systemic effects and, in particular, may contribute to the development of chemotherapy-induced mucositis.
Get full access to this article
View all access options for this article.
References
1.
Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut47(5):632–637, 2000.
2.
Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond)92(4):385–389, 1997.
3.
Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist3(6): 446–451, 1998.
4.
Fata F, Ron IG, Kemeny N, O’Reilly E, Klimstra D, Kelsen DP. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer86(7):1129–1134, 1999.
5.
Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Burns J, Keefe DM. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood)232(1):96–106, 2007.
6.
Von Bultzingslowen I, Adlerberth I, Wold AE, Dahlen G, Jontell M. Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria. Oral Microbiol Immunol18(5):278–284, 2003.
7.
Simon GL, Gorbach SL. Intestinal microflora. Med Clin North Am66(3):557–574, 1982.
8.
Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology86(1):174–193, 1984.
9.
Simon GL, Gorbach SL. The human intestinal microflora. Dig Dis Sci31(9 Suppl):147S–162S, 1986.
10.
Gustafsson BE. The physiological importance of the colonic microflora. Scand J Gastroenterol Suppl77:117–131, 1982.
11.
Umesaki Y, Setoyama H. Structure of the intestinal flora responsible for development of the gut immune system in a rodent model. Microbes Infect2(11):1343–1351, 2000.
12.
Rhee KJ, Sethupathi P, Driks A, Lanning DK, Knight KL. Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. J Immunol172(2):1118–1124, 2004.
13.
Heller F, Duchmann R. Intestinal flora and mucosal immune responses. Int J Med Microbiol293(1):77–86, 2003.
14.
Robbe C, Capon C, Coddeville B, Michalski JC. Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J384(Pt 2):307–316, 2004.
15.
Specian RD, Oliver MG. Functional biology of intestinal goblet cells. Am J Physiol260(2 Pt 1):C183–C193, 1991.
16.
Deplancke B, Gaskins HR. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr73(6): 1131S–1141S, 2001.
17.
Gusils C, Morata V, Gonzalez S. Determination of bacterial adhesion to intestinal mucus. Methods Mol Biol268:411–415, 2004.
18.
Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst87(24):1876–1883, 1995.
19.
Verburg M, Renes IB, Meijer HP, Taminiau JA, Buller HA, Einerhand AW, Dekker J. Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol Gastrointest Liver Physiol279(5):G1037–G1047, 2000.
20.
Leiper K, Campbell BJ, Jenkinson MD, Milton J, Yu LG, Democratis J, Rhodes JM. Interaction between bacterial peptides, neutrophils and goblet cells: a possible mechanism for neutrophil recruitment and goblet cell depletion in colitis. Clin Sci (Lond)101(4):395–402, 2001.
21.
Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol18(9):1095–1100, 2003.
22.
Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res58(5):933–939, 1998.
23.
Meslin JC, Fontaine N, Andrieux C. Variation of mucin distribution in the rat intestine, caecum and colon: effect of the bacterial flora. Comp Biochem Physiol A Mol Integr Physiol123(3):235–239, 1999.
24.
Cool JC, Dyer JL, Xian CJ, Butler RN, Geier MS, Howarth GS. Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Horm IGF Res15(1):72–82, 2005.
25.
Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther7(7):1139–1145, 2008.
26.
Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol63(2):239–251, 2009.
27.
Barcelo A, Claustre J, Moro F, Chayvialle JA, Cuber JC, Plaisancie P. Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut46(2):218–224, 2000.
28.
Layton A, McKay L, Williams D, Garrett V, Gentry R, Sayler G. Development of Bacteroides 16S rRNA gene TaqMan-based real-time PCR assays for estimation of total, human, and bovine fecal pollution in water. Appl Environ Microbiol72(6):4214–4224, 2006.
29.
Penders J, Vink C, Driessen C, London N, Thijs C, Stobberingh EE. Quantification of Bifidobacterium spp., Escherichia coli and Clostridium difficile in faecal samples of breast-fed and formula-fed infants by real-time PCR. FEMS Microbiol Lett243(1):141–147, 2005.
30.
Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol97(6):1166–1177, 2004.
31.
Sakai H, Procop GW, Kobayashi N, Togawa D, Wilson DA, Borden L, Krebs V, Bauer TW. Simultaneous detection of Staphylococcus aureus and coagulase-negative staphylococci in positive blood cultures by real-time PCR with two fluorescence resonance energy transfer probe sets. J Clin Microbiol42(12):5739–5744, 2004.
32.
Bodet CA 3rd, Jorgensen JH, Drutz DJ. Antibacterial activities of antineoplastic agents. Antimicrob Agents Chemother28(3):437–439, 1985.
33.
Milles S, Muggia A, Spiro H. Colonic histologic changes induced by 5-Fluorouracil. Gastroenterology43(1):391–399, 1962.
34.
Saegusa Y, Ichikawa T, Iwai T, Goso Y, Okayasu I, Ikezawa T, Shikama N, Saigenji K, Ishihara K. Changes in the mucus barrier of the rat during 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol43(1):59–63, 2008.
35.
Plaisancie P, Bosshard A, Meslin JC, Cuber JC. Colonic mucin discharge by a cholinergic agonist, prostaglandins, and peptide YY in the isolated vascularly perfused rat colon. Digestion58(2):168–175, 1997.
Inomata A, Horii I, Suzuki K. 5-Fluorouracil-induced intestinal toxicity: what determines the severity of damage to murine intestinal crypt epithelia? Toxicol Lett133(2–3):231–240, 2002.
38.
Wei ZG, Li GX, Huang XC, Zhen L, Yu J, Deng HJ, Qing SH, Zhang C. Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. World J Gastroenterol14(14):2179–2186, 2008.
39.
Nomoto K, Yokokura T, Mitsuyama M, Yoshikai Y, Nomoto K. Prevention of indigenous infection of mice with Escherichia coli by nonspecific immunostimulation. Antimicrob Agents Chemother36(2): 361–367, 1992.
40.
Nomoto K, Yokokura T, Nomoto K. Prevention of 5-fluorouracil-induced infection with indigenous Escherichia coli in tumor-bearing mice by nonspecific immunostimulation. Can J Microbiol38(8):774–778, 1992.
41.
Tancrede CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis152(1):99–103, 1985.
42.
Wells CL, Ferrieri P, Weisdorf DJ, Rhame FS. The importance of surveillance stool cultures during periods of severe neutropenia. Infect Control8(8):317–319, 1987.
43.
Quigley EM. Probiotics in the management of colonic disorders. Curr Gastroenterol Rep9(5):434–440, 2007.
